In 2014, a small phase 2 study revealed that single-agent bevacizumab, which targets vascular endothelial growth factor (VEGF), produced results in recurrent sex-cord stromal tumours (SCST) that showed a 17% response rate, 94% clinical benefit rate, and a median PFS of 9.3 months20. Here, VEGFA is linked to sex cord-stromal tumor.